Rituximab shows promise in preventing vasculitis relapses
NCT ID NCT00748644
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether rituximab, a targeted antibody therapy, is better than azathioprine, a standard immune-suppressing drug, at preventing relapses in people with ANCA-associated vasculitis. 117 patients who had achieved remission were randomly assigned to receive either rituximab infusions or azathioprine pills over 18 months. The main goal was to see how many had a major relapse during treatment and follow-up.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rituximab
- What this could lead to
- If successful, rituximab could become a standard maintenance therapy to prevent relapses in vasculitis patients, reducing the need for long-term steroids.
- What could go wrong
- This is a Phase 3 trial, but results may not apply to all patients. Rituximab can cause infusion reactions and increase infection risk. The study is completed, so findings are available but not yet widely implemented.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MICROSCOPIC POLYANGIITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopital Cochin
Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a diabetes drug shield kidneys from autoimmune attack?
- Promising vasculitis drug trial halted early
- Experimental liquid drug tested in ventilator patients with rare lung bleeding disease
- Hydroxychloroquine trial for rare vasculitis halted early
- Scientists build tissue bank to unlock vasculitis mysteries
- DNA hunt for vasculitis genes opens new doors